Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it

Steven P. Rowe, Andrew F. Voter, Rudolf A. Werner, Katherine A. Zukotynski, Martin G. Pomper, Michael A. Gorin, Lilja B. Solnes

Research output: Contribution to journalArticlepeer-review


Prostate cancer is the second most common malignancy in men with more than one million new cases diagnosed worldwide each year.1 Accurate diagnostic imaging for staging and re-staging of men with prostate cancer is paramount and this need has recently been at least partly addressed by the widespread adoption of center, registration trials, OSPREY (patient population: highrisk primary staging) and CONDOR (patient population: biochemical recurrence). In this manuscript, we will (1) review key findings from the OSPREY and CONDOR trials, (2) discuss the clinical acquisition protocol we use for 18F-DCFPyL PET scanning, (3) present information on important pearls and pitfalls, (4) provide an overview of the PSMA reporting and data system (PSMA-RADS) interpretive framework, and (5) posit important future directions for research in PSMA PET.

Original languageEnglish (US)
Pages (from-to)11432-11437
Number of pages6
JournalCanadian Journal of Urology
Issue number1
StatePublished - 2023


  • PSMA
  • prostate cancer
  • prostate-specific membrane antigen

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Image acquisition and interpretation of 18F-DCFPyL (piflufolastat F 18) PET/CT: How we do it'. Together they form a unique fingerprint.

Cite this